PI
ABUS icon

PEAK6 Investments’s Arbutus Biopharma ABUS Stock Holding History

PEAK6 Investments’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,500
Closed -$68.2K – 3837
2023
Q1 		$68.2K Sell
22,500
-177,800
-89% -$502K ﹤0.01% 3659
2022
Q4 		$467K Buy
200,300
+43,500
+28% +$104K ﹤0.01% 2582
2022
Q3 		$299K Buy
+156,800
New +$369K ﹤0.01% 3354
2022
Q1 		– Sell
-40,000
Closed -$156K – 5095
2021
Q4 		$156K Hold
40,000
– – ﹤0.01% 4147
2021
Q3 		$172K Buy
+40,000
New +$133K ﹤0.01% 4088

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PEAK6 Investments's ABUS Position: Q4 2022 in Review

PEAK6 Investments sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 62,400 shares — an estimated $149K sold.

PEAK6 Investments first reported a position in ABUS in Q3 2022 and held it in 1 quarter. The position peaked at $119K in Q3 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • PEAK6 Investments reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • PEAK6 Investments sold 62,400 Arbutus Biopharma shares in Q4 2022, an estimated $149K.
  • PEAK6 Investments first reported a position in Arbutus Biopharma in Q3 2022 and held it in 1 quarter.
  • PEAK6 Investments's Arbutus Biopharma position peaked at $119K in Q3 2022.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on PEAK6 Investments's 13F filing for Q4 2022, filed 10 Feb 2023.